Security
Tevogen Inc. Warrant · TVGNW
TVGNWNASDAQWarrantCurrentCIK 1860871Updated Oct 6, 2026
Name history
Tevogen Bio Holdings Inc. · through Jul 30, 2026Semper Paratus Acquisition Corp · through Feb 15, 2024
TVGNW price & chart
Loading TradingView…
NASDAQ:TVGNW on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
4 filing
Other Events
Items 8.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.03, 5.07, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 4,382,994Source | 3,461,675Source | 17,037,333Source | 357,138,356Source |
| Property, Plant and Equipment, NetUSD | 170,308Source | 296,442Source | 458,651Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 0Source | 0Source | — | 129,186Source |
| Assets, CurrentUSD | 1,539,783Source | 2,360,902Source | 355,836Source | 274,356Source |
| Prepaid Expense and Other Assets, CurrentUSD | 828,592Source | 919,088Source | 2,501Source | 145,170Source |
| Operating Lease, Right-of-Use AssetUSD | 1,423,473Source | 228,490Source | — | — |
| Other Assets, NoncurrentUSD | 1,065,884Source | 575,841Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 12,617,720Source | 10,135,680Source | 17,733,130Source | 15,057,704Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 402Source | 17,800Source | — | — |
| Additional Paid in CapitalUSD | 122,625,431Source | 97,893,322Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -139,660,549Source | -113,385,117Source | -17,378,637Source | -14,784,691Source |
| Stockholders' Equity Attributable to ParentUSD | -8,234,726Source | -6,674,005Source | -17,377,294Source | -14,783,348Source |
| Liabilities and EquityUSD | 4,382,994Source | 3,461,675Source | 17,037,333Source | 357,138,356Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 7,068,491Source | 9,042,704Source | 3,004,130Source | 350,454Source |
| Operating Lease, Liability, CurrentUSD | 327,740Source | 229,063Source | — | — |
| Accounts Payable, CurrentUSD | 3,340,127Source | 5,200,245Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | 1,122,750Source | 5,796Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,499,624Source | 1,712,396Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 4,408,361Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 16,222,861Source | 40,764,136Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -12,328,577Source | -11,998,730Source | -1,376,351Source | -215,395Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -64,439Source | — | 342,916,930Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 64,439Source | — | — | — |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | 342,984,430Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 11,662,393Source | 12,229,328Source | -341,660,930Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -730,623Source | 230,598Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 552,372Source | 1,282,995Source | 8,835Source | 129,186Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 16,222,861Source | 40,764,136Source | — | — |
| DepreciationUSD | 190,573Source | 162,209Source | — | — |
| General and Administrative ExpenseUSD | 15,028,929Source | 22,531,212Source | 2,273,970Source | 953,083Source |
| Income Tax Expense (Benefit)USD | 4,750Source | — | — | — |
| Investment Income, InterestUSD | — | — | 2,734,000Source | 4,948,000Source |
| Net Income (Loss) Attributable to ParentUSD | -26,275,432Source | -13,727,380Source | -67,325Source | 4,408,361Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -26,825,432Source | -10,273,695Source | — | — |
| Noncash Merger Related CostsUSD | — | 7,099,353Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 2,206,645Source | 5,361,444Source |
| Operating ExpensesUSD | 26,140,515Source | 53,564,488Source | — | — |
| Operating Lease, ExpenseUSD | 1,096,646Source | 1,065,784Source | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | 2,734,426Source | 4,948,194Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -26,140,515Source | -53,564,488Source | — | — |
| Income Tax Expense (Benefit)USD | 4,750Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -26,275,432Source | -13,727,380Source | -67,325Source | 4,408,361Source |
| Earnings Per Share, BasicUSD per share | -8.08Source | -0.07Source | — | — |
| Earnings Per Share, DilutedUSD per share | -8.08Source | -0.07Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 3,319,812Source | 146,672,534Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 3,319,812Source | 146,672,534Source | — | — |
| Additional Financial Items | ||||
| Business Combination, Acquisition Related CostsUSD | — | 7,499,353Source | — | — |
| Costs and ExpensesUSD | — | — | 2,273,970Source | 953,083Source |
| General and Administrative ExpenseUSD | 15,028,929Source | 22,531,212Source | 2,273,970Source | 953,083Source |
| Interest ExpenseUSD | — | 184,037Source | 256,031Source | — |
| Interest Income (Expense), NetUSD | -195,618Source | — | — | — |
| Investment Income, InterestUSD | — | — | 2,734,000Source | 4,948,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -26,825,432Source | -10,273,695Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 2,206,645Source | 5,361,444Source |
| Operating ExpensesUSD | 26,140,515Source | 53,564,488Source | — | — |
| Operating Lease, ExpenseUSD | 1,096,646Source | 1,065,784Source | — | — |
| Research and Development ExpenseUSD | 11,111,586Source | 31,033,276Source | — | — |
Offerings
Registration 333-296760
Filing attachments
ex99-1.htm · 8-K · 2026-09-30
Exhibit 99.1 Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements Both previously disclosed Nasdaq compliance matters are now closed September 30, 2026 WARREN, N.J., Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN ), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it received written notice from …
Read attachment ↗ex107.htm · S-8 · 2026-08-24
Calculation of Filing Fee Tables S-8 Tevogen Inc. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ────────────────────────────────────────────────────…
Read attachment ↗ex107.htm · S-8 · 2026-07-10
Calculation of Filing Fee Tables S-8 Tevogen Bio Holdings Inc. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ───────────────────────────────────────…
Read attachment ↗ex107.htm · S-3 · 2026-06-12
Calculation of Filing Fee Tables S-3 Tevogen Bio Holdings Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Off…
Read attachment ↗ex4-1.htm · 10-Q · 2026-05-15
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A …
Read attachment ↗ex99-1.htm · 8-K · 2026-03-04
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Tevogen Announces Reverse Stock Split March 4, 2026 WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of its common stock at a ratio of 50 for 1. Stockholders previously approved the reverse stock split on February 19, 2026, and provided the Board with discretion to determine the final reverse stock split ratio. The reverse …
Read attachment ↗